Clinical Study Data Request Registered Users, Please Login

The table below provides details of approved research proposals that have signed Data Sharing Agreements.

Proposal number Study sponsor(s) Title Lead researcher  
611 GSK Long-acting beta2-agonists for chronic obstructive pulmonary disease Kayleigh Kew Further Details
628 GSK Predictive and Prognostic Value of Blood Cell Ratios in Patients with Metastatic Renal Cell Carcinoma Treated with Pazopanib Arnoud J.Templeton, MD Further Details
631 GSK Predictors of BPH Progression Stephen Freedland, MD Further Details
637 GSK Relationship of Activated Clotting Time and Bleeding Related Outcomes in the FUTURA OASIS-8 Trial Sripal Bangalore, MD, MHA, FACC, FSCAI Further Details
639 GSK Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux in Patients with Peripheral Arterial Disease Saurav Chatterjee, MD Further Details
645 GSK The Influence of Age, Gender, and Race on the Effects of Combination Therapy with Carvedilol plus Lisinopril Versus Lisinopril Monotherapy for Systemic Hypertension Partha Sardar Further Details
646 GSK Factors influencing immune response and patient outcomes following influenza vaccination Dr. Subhadra Rajanaidu Further Details
647 GSK Assessing and Reporting Heterogeneity of Treatment Effect in Randomized Clinical Trials David M. Kent, MD, MSc Further Details
651 GSK Descriptive evaluation of SAE reporting rates in vaccine clinical trials among Latin American children Thomas Verstraeten Further Details
653 GSK Functional Estimation of Interventional Effects Joon Park Further Details
654 GSK Development of Population Pharmacokinetic/Pharmacodynamic Models for Pazopanib within the EuroTARGET project (Workpackage 7) Ulrich Jaehde, PhD Further Details
657 GSK Use of Heparins in patients with Cancer: Individual patient-data meta-analysis of randomized trials Holger Schunemann, MD, MSc, PhD Further Details
668 GSK Associations between antihypertensive drugs and patterns of blood pressure changes: a strategy to reduce the burden of anti-VEGF induced hypertension Arduino A Mangoni Further Details
669 GSK A multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression - efficacy and adverse outcomes Jon Jureidini Further Details
672 GSK The Development of Toxicity Prediction Tools to Assist Oncologists in the Management of Adverse Events in Patients Receiving Treatment with Lapatinib Dr. Mario Lacouture Further Details
674 GSK Antiepileptic drug monotherapy for epilepsy: an overview of systematic reviews and network meta-analysis Antony Marson Further Details
675 GSK Validation study on magnitude of tumor shrinkage as a prognostic marker Viktor Grünwald, MD Further Details
679 GSK An Epigenetic Analysis of the ALOX5 Gene Related to the Clinical Response to Montelukast Wayne H Anderson, PhD Further Details
681 GSK A randomized, double blind, placebo-controlled trial to evaluate the effect of rosiglitazone on metabolic markers in psoriasis patients Alexa B. Kimball Further Details
911 GSK Outcome Measures in Systemic Lupus Erythematosus: Constructing a Meaningful Response Index from Existing Clinical Trial Data Lindsy Forbess, MD, MSc Further Details
918 GSK Outcomes after Percutaneous Coronary Intervention in Cancer patients with Acute Coronary Syndrome Partha Sardar MD Further Details
928 GSK Lung function and airway inflammation response after ozone exposure 0.25ppm Krista Todoric, MD Further Details
930 GSK MASTERMIND: Stratification of glycaemic response the ADOPT and RECORD studies Professor Andrew Hattersley, M.D. FRS Further Details
945 ViiV Healthcare The CD4/CD8 Ratio as a Predictor of Non-AIDS Events During Antiretroviral Therapy: Confirmation of its Predictive Value and Impact of Maraviroc in Treatment-Experienced Patients Santiago Moreno Further Details
946 Novartis/Roche Assessing models for changes in tumour size over time and how they relate to survival times Raluca Eftimie, PhD Further Details
951 GSK Optimized Eltrombopag Treatment of Hepatitis C virus-related thrombocytopenia Mohammad Saleh Further Details
955 GSK A study of subgroup identification and micro aggregation S. Stanley Young Further Details
956 Roche Bone Quality Project Dennis M. Black Further Details
976 GSK 5-alpha reductase inhibitor use and risk of lung cancer Marshall Pitz, MD FRCPC Further Details
977 GSK The implication of central adjudication of COPD exacerbations by experts for treatment effect estimates and sample size calculation Milo Puhan Further Details
980 GSK Association of leukotriene C4 synthase gene (rs730012, -444 A/C) polymorphism with response to leukotriene modifiers treatment in asthma patients Yi-Fan Wu Further Details
982 ViiV Healthcare Pharmacokinetic modeling of dolutegravir in HIV patients V P Subramanyam Rallabandi Further Details
988 Roche PhD Project: Bayesian Multivariate Network Meta-Analysis of Ordered Categorical Data Fabrizio Messina Further Details
989 GSK Assessing at the participant level the applicability of clinical trials to a specific patient Amos Cahan Further Details
995 BI / GSK / Lilly / Roche / Takeda / UCB Identifying immune modulating patterns across diseases from open clinical trial data Dr Atul J. Butte Further Details
997 GSK Predictors of Prostate Cancer Progression Among Men on Active Surveillance Stephen Freedland, MD Further Details
998 GSK Determination of minimally important difference for short form 36 and Facit Fatigue for Systemic lupus erythematosus Meenakshi Jolly, MD, MSCP Further Details
999 BI / GSK Assessing the Comparative Efficacy of Therapeutics for Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of Randomized Trials Kristen M. Sweet Further Details
1000 GSK Review of fever and febrile convulsion rates in children after trivalent influenza vaccine. Dr Jean Li-Kim-Moy, MBBS, FRACP Further Details
1002 GSK Long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease Michael Sarai Further Details
1013 GSK Biopsy Avoidance in Patients At Risk For Prostate Cancer and in Patients With Low Risk Prostate Cancer: Developing Tools for Personalized Medicine Girish Kilkarni, MD, PhD Further Details
1015 GSK Pazopanib induced liver toxicity: incidence, pathogenesis and value of liver enzymes increase as a predictor of outcome in metastatic soft tissues sarcoma patients. A retrospective multi-centric study Bruno Vincenzi, MD, PhD Further Details
1016 GSK Statistical methods for estimating the duration of protection of malaria vaccines: secondary analysis of data from the RTSS/AS02A trial in Mozambique. Paul Milligan Further Details
1020 GSK Genomic prediction tools developed using phenotypes from disease progression models Manish Sharma, MD Further Details
1022 Novartis Prediction of maximal work load (Wmax)in a bicycle test in patients with COPD. Göran Eriksson Further Details
1028 ViiV Healthcare Impact of dolutegravir on CD4+/CD8+ ratio and CD4+ percentage in HIV-infected naive patients. José Ramón Blanco, MD, PhD Further Details
1053 GSK Validation of the spirometric LMS equations in the Spanish population Dr. Patricia Sobradillo Further Details
1057 Novartis Health-related utility and disutility value in metastatic renal cell carcinoma patient treated with pazopanib Chang Wook Jeong Further Details
1058 ViiV Healthcare Ritonavir-boosted protease inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimens: a systematic review and individual patient data meta-analysis Alvaro H Borges, MD, MSc Further Details
1071 BI/GSK Optimising the Analysis of vascular Prevention trials (OA-Prevention) Professor Philip Bath Further Details
1073 GSK End-of-life trajectories in COPD Dr. Daisy J.A. Janssen Further Details
1075 Roche Efficacy and Safety of Bevacizumab in the Elderly Cancer Patients: Pooled Analysis of Ten Randomized Clinical Trials Xiaofei Wang Further Details
1078 Lilly Nocebo effects in the treatment of bipolar disorder: Results from an individual study participant level meta-analysis of the placebo arm of olanzapine clinical trials Seetal Dodd Further Details
1079 ViiV Healthcare The effects of maraviroc versus efavirenz in combination with zidovudine/abacavir on the CD4/CD8 ratio in treatment-naïve HIV-infected individuals. Sergio Serrano-Villar, MD PhD Further Details
1084 GSK Studies on the relationship between corticosteroids and unfavorable medical effects. A study based on the BLISS-52 and BLISS-76 clinical trials. Ronald van Vollenhoven, MD, PhD Further Details
1085 Roche Optimized peg-interferon alpha-2a Treatment of Hepatitis C and Hepatitis B Mohammad I Saleh, PhD Further Details
1086 ViiV Healthcare Abacavir HLA-B*57:01 tolerance and genetic variation within the MHC. Elizabeth Phillips, MD Further Details
1088 GSK A study to identify risk factors that modify Rotarix efficacy and influence the time to rotavirus gastroenteritis among vaccinated and unvaccinated African infants. Joann Gruber Further Details
1090 GSK Validating the test-negative case-control design for estimating rotavirus vaccine effectiveness using gold-standard randomized controlled trial data from South Africa and Malawi (Rota-037). M. Elizabeth Halloran Further Details
1100 BI PRoFESS blood pressure variability and risk of intracerebral hemorrhage Dr. Jacoba P Greving Further Details
1103 GSK A study on the possible association between antidepressant response to SSRIs and proneness for side effects Elias Eriksson, MD, PhD Further Details
1108 GSK Correlation between SF-36 PCS and MCS scores and SELENA SLEDAI activity score in SLE: a meta-analysis. Chaigne Benjamin, MD Further Details
1125 Lilly Meta-analysis of the risk of relapse in bipolar disorder Stefan Leucht Further Details
1128 GSK EuroTARGET GWAS on sunitinib pharmacogenetics in patients with metastatic renal cell carcinoma. Prof. H.J. Guchelaar Further Details
1062/1130 GSK/UCB Factors that determine placebo response in epilepsy trials Emilia Bagiella Further Details
1132 GSK Cytokine patterns in anti-viral disease vaccines: a knowledge driven approach Atul J. Butte, MD, PhD Further Details
1134 GSK Incidence rate and risk factors associated with Hepatocellular carcinoma development in patients with Chronic Hepatitis C and severe thrombocytopenia: the lesson from Enable studies Prof. Savino Bruno, MD Further Details
1136 Takeda Can Machine Learning Algorithms using General Labs Predict Clinical Remission and Mucosal Healing for Patients on Vedolizumab? Peter Higgins Further Details
1137 GSK Immunotherapy trial simulators: Using mathematical, computational and statistical techniques to simulate trial design for new products in the treatment, vaccination and immunoprophylaxis of disease. Roy Anderson, PhD Further Details
1140 BI Evaluation of the effect of incidental beta blocker use on clinical response to the EGFR TKI, afatinib John Heymach, MD, PhD Further Details
1141 GSK Multivariate methods for meta-analysis of vaccine studies with multiple correlated outcomes Merryn Voysey Further Details
1142 BI / GSK / UCB A meta-analysis of Parkinson’s disease Atul Butte Further Details
1148 Lilly Initial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual participant level analyses of placebo-controlled studies. Dr. Joaquim Radua Further Details
1152 BI Advanced analytic methods to refine phenotyping and risk prediction among patients with atrial fibrillation in the RE-LY trial. Nihar Desai, MD, MPH Further Details
1154 GSK Developing New Outcome Measures for SLE by Deconvoluting Available Datasets. Peter E. Lipsky, MD Further Details
1157 Novartis Quality-adjusted survival analysis for patients with metastatic renal cell carcinoma treated in a phase III trial of pazopanib versus sunitinib (COMPARZ trial) Chang Wook Jeong Further Details
1159 ViiV Healthcare Validation of Pharmacokinetic/Viral Dynamic Modeling and Simulation using the Dolutegravir Phase IIa Dataset. Edward P. Acosta, Pharm.D. Further Details
1160 BI Development of a clinical decision support tool to identify patients at high risk of early or late bleeding complications from anticoagulation. Mark H. Ebell MD, MS Further Details
1161 Roche Novel approaches to the prediction of influenza complications Mark H. Ebell MD, MS Further Details
1173 GSK/Lilly Initial severity and antidepressant efficacy for anxiety disorders: an individual patient data meta-analysis. Ymkje Anna de Vries Further Details
1180 Novartis Evaluation of a platelet count threshold for bleeding risk in thrombocytopenic patients with chronic liver disease who undergo diagnostic and therapeutic invasive procedures. Edoardo G. Giannini Further Details
1186 Novartis Using generalized pairwise comparisons to assess the benefit/risk balance of pazopanib vs sunitinib for patients with advanced or metastatic renal cell carcinoma Marc Buyse Further Details
1206 GSK Efficacy of Belimumab on Mucocutaneous Involvement in Patients with Systemic Lupus Erythematosus (MUCOBEL) Kuhn, Annegret Further Details
1224 GSK Interaction between Meningococcal Serogroup B Vaccine (Bexsero™) and routine infant vaccines on the risk of occurrence and recurrence of adverse events following immunization. Gaston De Serres Further Details
1234 Lilly Placebo Response in Pediatric Generalized Anxiety Disorder Jeffrey Strawn Further Details
1236 GSK COPERNICUS re-analysis John Cleland Further Details
1250 BI/Lilly The relationship of treatment effects and per capita income of study countries in duloxetine trials in the treatment of depressed patients. Markus Koesters Further Details
1256 GSK Population mechanistic heamatotoxicity modeling of Dapsone in G6PD deficiency patients Joel Tarning Further Details
1257 GSK An independent evaluation of the cardiovascular risk of rosiglitazone: meta-analysis of GSK’s publicly available clinical trial data Joseph S. Ross, MD, MHS Further Details
1258 Roche Advance lung cancer inflammation index (ALI) in metastatic non-squamous lung cancer: A validation study Syed Hasan Raza Jafri Further Details
1273 GSK Post-hoc analysis of placebo-controlled trials in children and adolescents with depression Elias Eriksson Further Details
1277 Roche Immunotherapy trial simulators: Using mathematical, computational and statistical techniques to simulate trial design for new products in the treatment, vaccination and immunoprophylaxis of disease. Roy Anderson Further Details
1280 GSK Placebo and nocebo effects in migraine Ver 2 Paul Enck Further Details
1286 BI Predictors of new onset atrial fibrillation and recurrent ischemic events in patients with ischemic stroke Adnan I. Qureshi, MD Further Details
1292 Lilly Item Response Theory for Clinical ADHD Research Alex Sturm Further Details
1295 BI / GSK A Swapping Method Based on Covariate Classification for Average Treatment Effect Estimation. Dr. Bimal Sinha Further Details
1307 Takeda The Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus in Patients with Chronic Kidney Disease Dr. Navdeep Tangri Further Details
1316 BI Blinding (Masking) and the Placebo Effect James Brian Byrd, MD, MS, FAHA, FACC Further Details
1320 GSK Utility of a measure of Lupus Low Disease Activity State in SLE Pei Xuan Ong (Emily) Further Details
1321 GSK Bone Quality Project Dennis M. Black Further Details
1322 GSK Comparative efficacy of different therapeutic approaches in the "naïve" patient with chronic obstructive pulmonary disease (COPD): analysis of patient-level data Giulio Pareto Further Details
1323 Lilly Detection of uninformative clinics during the trial of a new drug using statistical and machine learning techniques Praveen Deorani Further Details
1326 Lilly Reliability and Validity of the Parent Rating of Evening and Morning Behavior Scale, Revised Steven V. Faraone, Ph.D. Further Details
1331 BI Impact of baseline diabetes and obesity statuses on outcomes post-ischemic stroke. Colleen Bauza Further Details
1335 GSK / UCB Investigation into the natural course of epilepsy and the implications on clinical trials Daniel Goldenholz Further Details
924/1341 BI/GSK/Novartis Vol-PACT: Improving Volumetric CT Metrics for Precision Analysis of Clinical Trial Results Geoffrey R. Oxnard Further Details
1343 GSK Improving the Assessment of Systemic Lupus Erythematosus Disease Activity Zahi Touma Further Details
1373 GSK An exploratory analysis of headache in placebo controlled trials of paroxetine for generalized anxiety disorder Jonathan H. Smith, M.D. Further Details
1374 GSK A novel representation of vaccine efficacy trial datasets for use in computer simulation of vaccination policy Michael M. Wagner Further Details
1377 BI/GSK/Lilly/Takeda The association between patient outcomes under two treatments (ABOUT) in cross-over trials Marc Buyse, ScD Further Details
1387 GSK Sex-differences in immunogenicity, reactogenicity and efficacy in response to vaccines in infants and young children. Merryn Voysey Further Details
1393 Roche Prognostic influence of body mass index and body weight gain in colorectal cancer patients treated with adjuvant chemotherapy: data from The AVANT study Sae-Won Han Further Details
1401 Sanofi Use of Heparins in patients with Cancer: Individual patient-data meta-analysis of randomized trials Holger Schunemann Further Details
1403 ViiV Healthcare Mathematical modeling of the HIV transmission risk during the first 24 weeks after initiation of antiretroviral therapy in naïve HIV-infected MSM: comparison of INSTI-based regimens vs. nnRTI and PI based regimens. Juan Berenguer Further Details
1421 GSK Cost utility analysis comparing belimumab against rituximab in systemic lupus erythematosus Chris Gillette Further Details
1422 UCB Developing new outcome measures for SLE by deconvoluting available data sets Peter E. Lipsky, MD Further Details
1428 BI Estimating absolute treatment effect of dabigatran 110 mg bid vs. 150 mg bid (vs. warfarin) for individual patients with atrial fibrillation. Frank L.J. Visseren Further Details
1430 GSK Comparison of various remission criteria for SLE. A study based on the BLISS-52 and BLISS-76 clinical trials. Ronald van Vollenhoven Further Details
1433 BI / Lilly / Roche Identification of patient subgroups with enhanced treatment response in RCTs with time-to-event outcomes: use of counterfactual restricted survival times. Ludovic Trinquart Further Details
1450 BI / Novartis Understanding effectiveness of new drugs in older adults shortly after market entry. Shirley V Wang Further Details
1451 GSK Assessment of bias from treatment discontinuation on mortality and exacerbations in the Towards a Revolution in COPD Health (TORCH) randomized trial Samy Suissa Further Details
1452 GSK A study to determine if prior rotavirus exposure modifies the effect of rotavirus vaccines given to infants in low- and middle-income African countries Sylvia Becker-Dreps Further Details
1455 BI Prediction of major bleeding in atrial fibrillation patients with a history of stroke or transient ischemic attack Jacoba Greving Further Details
1456 VIIV Impact of ongoing side effects on the efficacy of initial antiretroviral therapy Andrew Carr Further Details
1457 Lilly Initial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual participant level analyses of placebo-controlled studies. Stefan Leucht Further Details
1461 Lilly Regression discontinuity designs to evaluate real-world clinical effectiveness: a case study of drotrecogin alpha Allan J. Walkey Further Details
1470 Takeda / UCB The efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease Shomron Ben-Horin M.D. Further Details
1473 Roche Comparison of the pharmacokinetics of oral once-monthly 150mg ibandronate between ethnic Europeans and Taiwan post-menopausal osteoporotic women across two phase 1 studies Keh-Sung Tsai Further Details
1475 BI Predicting safety and efficacy of afatinib treatment of NSCLC Assoc/Prof Michael Sorich Further Details
1481 GSK Efficacy and safety of belimumab in childhood-onset lupus Dr Anca Askanase MD, MPH Further Details
1514 Roche Gain of quality-adjusted life year in patients with neovascular age-related macular degeneration after anti-VEGF treatment Park, Sang Jun Further Details
1526 GSK Assessment of correlations among all favourable and unfavourable effects for rosiglitazone/metformin, and for metformin alone, in Type 2 diabetes Lawrence D Phillips Further Details
1528 GSK / Lilly / Roche A Swapping Method for Average Treatment Effect Estimation Bimal Sinha Further Details
1540 GSK IMPROVING METHODS. Our research focus is to optimize the translation of clinical trial results into clinical practice Dr. Issa Dahabreh Further Details
1541 Roche Item calibration of the NEI VFQ-25 to improve future comparative research using patient-reported outcome (PRO) measures. Judith E. Goldstein Further Details
1542 BI Optimising the Analysis of vascular Prevention trials (OA-Prevention) Philip Bath Further Details
1558 GSK/Novartis Development of historical control using placebo data from pediatric epilepsy studies Anthony Daniels Further Details
1566 Lilly A microanalysis of symptoms and behaviors defining ADHD in adults and their response to both active medication and placebo Frederick W. Reimherr MD Further Details
1567 BI / Takeda Stratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetes Andrew Hattersley Further Details
1572 BI/Eisai/GSK/Lilly Research to evaluate the relation of toxicity and the relative dose intensity in phase I trials beyond cycle 1 of Molecular Targeted Agents (MTAs) Kan Yonemori, MD., PhD Further Details
1569 GSK Melancholic symptoms in bipolar depression and response to lamotrigine Dr. Evyn Peters Further Details
1575 GSK/Lilly Early improvement in individual symptoms and response to antidepressants in patients with major depressive disorder Ymkje Anna de Vries Further Details
1581 GSK MASTERMIND: Assessing the cost effectiveness of a stratified approach to type 2 diabetes therapy Professor Chris Jennison Further Details
1587 Astellas Sex-specific efficacy of mirabegron for overactive bladder (OAB) symptoms: individual patient data meta-analyses Marco H. Blanker, MD PhD Further Details
1593 GSK JANUVIA/JANUMET HTA Submission(Germany) Dr. Rainer Woker Further Details
1595 BI / GSK / Lilly / Roche A Novel Approach to Developing Comprehensive Profile of Adverse Event (AE) Data from Clinical Trials Sharayu Paranjpe Further Details
1599 Roche Predictors of exposure, adverse and therapeutic effects of BRAF/MEK inhibitors in advanced melanoma. Michael Sorich Further Details
1600 Lilly Item factor analysis of the SNAP-IV Parent Report Form: Generating item parameter estimates Alexandra Sturm, Ph.D. Further Details
1601 Sanofi / Roche Identification of clinical biomarkers for adjuvant chemotherapy for gastric cancer after D2 dissection by analyses of individual patents’ data from large randomized controlled trials Akira Tsuburaya, MD PhD Further Details
1622 ViiV A systematic literature review and Individual patient-level data enhanced network meta-analysis to determine the comparative efficacy and safety of first-line HIV antiretroviral therapies Steve Kanters Further Details
1624 Lilly A Meta-analysis of Tardive Dyskinesia Rates in Studies Comparing Second Generation Antipsychotics (SGAs) with each other or to First-Generation Antipsychotics (FGAs). Christoph U Correll Further Details
1629 GSK Sex-differences in immunogenicity, reactogenicity and efficacy in response to vaccines in infants and young children. Merryn Voysey Further Details
1630 GSK A framework for individualized prediction of the rate and severity of asthma exacerbations Mohsen Sadatsafavi Further Details
1633 ViiV Comparative effect of dolutegravir and raltegravir on CD4+/CD8+ ratio, CD4%, and multiple T-cell marker recovery. SPRING-2 study. Jose Ramon Blanco Further Details
1637 Novartis 1618 - Optimizing Patient Reported Outcomes by Linking Study Endpoints to Real-World Benchmarks Dr. Jeffrey Lackner Further Details
1640 GSK Effect of Fluticasone/Salmeterol on Chronic Bronchitis Symptoms and Associated Patient Reported Outcomes: a post-hoc analysis of the TORCH trial Victor Kim Further Details
1643 Astellas / Lilly / Novartis / Roche Development of an accurate statistical method for evaluating region-specific treatment effects in multiregional clinical trials Hisashi Noma Further Details
1660 Sanofi Assessing the generalizability of all-cause mortality from the MOSAIC trial to older adults diagnosed with stage II and III colon cancer in SEER-Medicare Jennifer L. Lund Further Details
1668 Roche Quantitative Evaluation of Circadian Rhythm of Serum Glucose Level in Caucasian and Chinese Type 2 Diabetic Patients (Oct/2016) Pei Hu Further Details
1675 Lilly Efficacy and tolerability of SNRIs in depression. Elias Eriksson Further Details
1684 Roche ANSELMA
Antiangiogenic agents in advanced non-small cell lung cancer patients who failed first-line chemotherapy: an individual patient data meta-analysis
Benjamin Besse Further Details
1688 Novartis Denis Collins
Translational data from LPT109096 to assess the impact of HER2-targeted therapies on HER-family and stem cell marker expression.
Benjamin Besse Further Details
1691 GSK Longitudinal Concurrent and Predictive Biomarkers of Clinical Disease Severity in Systemic Lupus Erythematosus in BLISS-52/BLISS-76 Austin Huang Further Details
1692 BI / GSK Predictors of chronic obstructive pulmonary disease progression Akihiro Hisaka Further Details
1695 GSK Outcome measures and baseline predictors of response to belimumab treatment Ioannis Parodis Further Details
1702 Lilly Comparative Effectiveness Analysis with Data From Randomized Clinical Trials and Observational Studies Herbert Pang Further Details
1707 Roche Pooled analysis of cardiac safety of T-DM1 in HER2-positive metastatic breast cancer patients Evandro de Azambuja Further Details
1721 Lilly / Roche Improving the evaluation of new cancer therapies to expedite patient access Professor Jonathan Karnon Further Details
1731 GSK Host characteristics impacting Rotarix immunogenicity and correlates of protection for rotavirus gastroenteritis, a multi-site pooled analysis of individual-level clinical trial data Julia M. Baker Further Details
1741 Lilly / Novartis / Roche Predictors of exposure, therapeutic and adverse effects of drugs used in the treatment of advanced breast cancer and advanced colorectal cancer. Dr Ashley Mark Hopkins Further Details
1752 GSK Sex Differences in responses to umeclidinium-vilanterol treatment in COPD patients Elisabetta Straface Further Details
1758 Novartis Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of Chronic Kidney Disease Lesley A. Inker, MD Further Details
1764 Sanofi / Takeda Personalized Medicine Model Builder and Evaluation for Diabetes Treatments Adam Kapelner Further Details
1779 GSK Evaluation of the effect of inhaled corticosteroids (ICS) on blood eosinophil count (EOS) in patients with COPD Professor Jørgen Vestbo DMSc FRCP FERS Further Details
1819 GSK Individual Participant Data Meta-analysis Of Antidepressant Trials For Major Depression In Japan Shigeto Yamawaki Further Details
1843 GSK The genetics of glycaemic response to GLP-1 receptor agonists in Type 2 diabetes Ewan Pearson Further Details
1844 GSK Real World Effects of Medications for Chronic Obstructive Pulmonary Disease Dr Kevin Wing Further Details
1847 Sanofi Antiangiogenic Second line Lung cancer Meta-Analysis (ANSELMA) - A meta-analysis on antiangiogenic agents in advanced non-small cell lung cancer patients who failed first-line chemotherapy. Benjamin Besse Further Details
1907 GSK Critical characterization of the impact of clinical-pathological tumoral features on recurrence risk dynamics of NSCLS. Tommaso De Pas Further Details
1928 GSK The development of a disease progression model to describe the long-term effects of anti-diabetic medications on Hemoglobin A1C Mohammad Saleh Further Details
1955 BI Development and validation of a model to predict absolute vascular risk reduction due to intensive blood-pressure targets in individual patients at baseline and after three months F.L.J. Visseren Further Details